A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Solid Tumor

In brief

This study is composed of phase I and IIa parts. The dose-escalation phase I part aims to find the maximum tolerated dose (MTD) and to identify the safety of CAR001 in subjects with relapsed/refractory solid tumor; the dose-expansion phase IIa part aims to evaluate the potential efficacy of CAR001 in subjects with relapsed/refractory non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) or Glioblastoma multiforme (GBM).

Key facts

Study ID: NCT06150885
Run by: Ever Supreme Bio Technology Co., Ltd.
People needed: 60
Starts: 2024-09-01
Expected to finish: 2027-09-30
Last updated by the study team: 2024-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female subjects aged ≥ 18 years
For phase I part, subjects with histologically confirmed diagnosis of solid tumor with expression of PD-L1 ≥ 1% and are relapsed/refractory to at least two lines of standard-of-care therapy. For phase IIa part, subjects with histologically confirmed diagnosis of TNBC, NSCLC, CRC or GBM with expression of PD-L1 ≥ 1%, and are relapsed/refractory to at least two lines of standard-of-care therapy.
With at least one measurable lesion as defined by RECIST1.1 (for TNBC, NSCLC or CRC) or RANO (for GBM)
Able to understand and sign the ICF
Have a life expectancy of > 12 weeks
ECOG performance status ≤ 1
Recovered from any previous therapy related toxicity to ≤ grade 2 at screening
With adequate renal function: serum creatinine ≤ 1.5 X ULN; eGFR > 50 ml/min
With adequate liver function: ALT, AST, and ALP ≤ 3X ULN or ≤ 5 X ULN if liver metastases; and total bilirubin ≤ 1.5X ULN or ≤ 3 X ULN if due to Gilbert's disease
With PT and PTT ≤ 1.5X ULN
With adequate hematopoietic function:
ANC ≥ 1,000 cells/μl
Platelets ≥ 75,000 counts/μl
Total WBC ≥ 2,000 cells/μl
Hemoglobin ≥ 8 g/dL

You may not qualify if…

Has received any allogeneic cell therapy before screening
With known or suspected to be hypersensitivity to CAR001 or its excipients, such as DMSO or human serum albumin
With more than one kind of active diagnosed primary cancer
With active infection requiring systemic medication
With medical conditions who are receiving systemic steroid therapy >10 mg prednisone/day or equivalent dose, or other immune-suppressants in the past 2 weeks
Has been diagnosed as HIV positive (confirmed by anti-HIV and nucleic acid test)
With acute cardiovascular disease; NYHA classification ≥ 3; or history of myocardial infarction during the past 6 months; or has active uncontrolled arterial hypertension by medical history. Per investigator's judgment, would not make participation appropriate
With historical or current auto-immune diseases, such as rheumatoid arthritis, type I diabetes, psoriasis or systemic lupus erythematosus
Has uncontrolled psychiatric disorder by medical history
Has CNS diseases except GBM or stroke
Has received any investigational therapy from another clinical study within 4 weeks
Inability to undergo radiological assessment, such as MRI or CT for any reason
Has received radiotherapy or chemotherapy within 2 weeks (but palliative radiation therapy (R/T) for pain control are allowed)
Not suitable to participate the trial as judged by the investigator
Female subject of childbearing potential who:
Is lactating; or
Has a positive pregnancy test result at eligibility checking; or
Refuses to adopt at least two form of birth control from signing informed consent to 1 year after the last administration of CAR001.
Male subject with a female spouse/partner who is of childbearing potential refuses to adopt at least two forms of birth control from signing informed consent to 1 year after the last administration of CAR001.
For exclusion criteria #15 and #16, acceptable forms of birth control include:
Established use of oral, injected, or implanted hormonal methods of contraception that have comparable efficacy (failure rate < 1 %), for example hormone vaginal ring or transdermal hormone contraception
Placement of an intrauterine device or intrauterine system
Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)

Where it is running

China Medical University Hospital — Taichung, Non-US, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.